文献速递甲状腺疾病

无论既往是否接受血管内皮生长因子受体靶向治疗及肿瘤组织学类型如何,卡博替尼对比安慰剂均提高放射性碘难治性分化型甲状腺癌患者的无进展生存期:COSMIC-311研究亚组分析

Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
PubMed 文献 · Thyroid · 2024-01-23

COSMIC-311研究纳入258例放射性碘难治性分化型甲状腺癌患者,按2:1随机分配至口服卡博替尼60 mg每日一次组或匹配安慰剂组,按既往治疗(仅索拉非尼、仅仑伐替尼、两者)和组织学类型(乳头状、滤泡状、嗜酸细胞型、低分化)进行亚组分析。结果显示,各亚组中卡博替尼组的无进展生存期和客观缓解率均优于安慰剂组,安全性结果与总体人群一致。

要点

  • 既往仅索拉非尼组中位无进展生存期卡博替尼16.6个月 vs 安慰剂3.2个月(HR 0.13,95%CI 0.06-0.26)。
  • 既往仅仑伐替尼组中位无进展生存期卡博替尼5.8个月 vs 安慰剂1.9个月(HR 0.28,95%CI 0.16-0.48)。
  • 既往两者均使用组中位无进展生存期卡博替尼7.6个月 vs 安慰剂1.9个月(HR 0.27,95%CI 0.13-0.54)。

核心结论

  • 结果表明,无论既往是否接受仑伐替尼或索拉非尼治疗或组织学类型如何,卡博替尼均使放射性碘难治性分化型甲状腺癌患者获益。

研究设计与样本

  • 3期COSMIC-311研究亚组分析,258例患者按2:1随机分配至口服卡博替尼60 mg片剂/日组(170例)或匹配安慰剂组(88例),分层因素为既往仑伐替尼使用(是/否)和年龄(≤65岁、>65岁)。

主要发现

  • 既往仅索拉非尼组(n=96)中位无进展生存期卡博替尼16.6个月 vs 安慰剂3.2个月(HR 0.13,95%CI 0.06-0.26)。
  • 既往仅仑伐替尼组(n=102)中位无进展生存期卡博替尼5.8个月 vs 安慰剂1.9个月(HR 0.28,95%CI 0.16-0.48)。
  • 既往两者均使用组(n=60)中位无进展生存期卡博替尼7.6个月 vs 安慰剂1.9个月(HR 0.27,95%CI 0.13-0.54)。
  • 乳头状癌(n=150)中位无进展生存期卡博替尼9.2个月 vs 安慰剂1.9个月(HR 0.27,95%CI 0.17-0.43);滤泡状癌(n=113例,含嗜酸细胞型43例和低分化36例)中位无进展生存期卡博替尼11.2个月 vs 安慰剂2.5个月(HR 0.18,95%CI 0.10-0.31)。
  • 嗜酸细胞型中位无进展生存期卡博替尼11.2个月 vs 安慰剂2.5个月(HR 0.06,95%CI 0.02-0.21);低分化型中位无进展生存期卡博替尼7.4个月 vs 安慰剂1.8个月(HR 0.18,95%CI 0.08-0.43)。

关键数值与推荐

  • 客观缓解率卡博替尼/安慰剂:既往仅索拉非尼组21%/0%,既往仅仑伐替尼组4%/0%,两者均使用组8%/0%。
  • 客观缓解率卡博替尼/安慰剂:乳头状癌15%/0%,滤泡状癌8%/0%,嗜酸细胞型11%/0%,低分化型9%/0%。
  • 中位随访时间10.1个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Lenvatinib and sorafenib are standard of care first-line treatments for advanced, radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC). However, most patients eventually become treatment-resistant and require additional therapies. The phase 3 COSMIC-311 study investigated cabozantinib in patients with RAIR DTC who progressed on lenvatinib, sorafenib, or both and showed that cabozantinib provided substantial clinical benefit. Presented in this study is an analysis of COSMIC-311 based on prior therapy and histology. Methods: Patients were randomized 2:1 (stratification: prior lenvatinib [yes/no]; age [≤65, >65 years]) to oral cabozantinib (60 mg tablet/day) or matched placebo. Eligible patients received 1-2 prior vascular endothelial growth factor receptor-targeting tyrosine kinase inhibitors for DTC (lenvatinib or sorafenib required), had a confirmed DTC diagnosis, and were refractory to or ineligible for radioiodine therapy. For this analysis, progression-free survival (PFS) and objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 by a blinded independent radiology committee were evaluated by prior therapy (lenvatinib only, sorafenib only, both) and histology (papillary, follicular, oncocytic, poorly differentiated). Results: Two hundred fifty-eight patients were randomized (170 cabozantinib/88 placebo) who previously received sorafenib only (n = 96), lenvatinib only (n = 102), or both (n = 60). The median follow-up was 10.1 months. The median PFS (months) with cabozantinib/placebo was 16.6/3.2 (sorafenib only: hazard ratio [HR] 0.13 [95% confidence interval, CI, 0.06-0.26]), 5.8/1.9 (lenvatinib only: HR 0.28 [95% CI 0.16-0.48]), and 7.6/1.9 (both: HR 0.27 [95% CI 0.13-0.54]). The ORR with cabozantinib/placebo was 21%/0% (sorafenib only), 4%/0% (lenvatinib only), and 8%/0% (both). Disease histology consisted of 150 papillary and 113 follicular, including 43 oncocytic and 36 poorly differentiated. The median PFS (months) with cabozantinib/placebo was 9.2/1.9 (papillary: HR 0.27 [95% CI 0.17-0.43]), 11.2/2.5 (follicular: HR 0.18 [95% CI 0.10-0.31]), 11.2/2.5 (oncocytic: HR 0.06 [95% CI 0.02-0.21]), and 7.4/1.8 (poorly differentiated: HR 0.18 [95% CI 0.08-0.43]). The ORR with cabozantinib/placebo was 15%/0% (papillary), 8%/0% (follicular), 11%/0% (oncocytic), and 9%/0% (poorly differentiated). Safety outcomes evaluated were consistent with those previously observed for the overall population. Conclusions: Results indicate that cabozantinib benefits patients with RAIR DTC, regardless of prior lenvatinib or sorafenib treatments or histology. Clinical Trial Registration Number: NCT03690388.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Capdevila J, Krajewska J, Hernando J, et al. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 2024. PMID: 38062732. doi:10.1089/thy.2023.0463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。